Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
374 Leser
Artikel bewerten:
(2)

Metabolon, Inc.: Metabolon Appoints Michael Irwin as Vice President, Global Head of Sales

Michael Irwin will drive Metabolon's global sales strategy as the company moves into its next phase of growth in the mutliomic marketplace

MORRISVILLE, N.C., Jan. 14, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces the appointment of Michael Irwin to Metabolon as Vice President, Global Head of Sales.


"We are thrilled to welcome Michael to the Metabolon leadership team during this pivotal time for the company. Michael comes to Metabolon from Olink, where he was head of global sales. As the life sciences industry moves towards a multiomic research approach, Michael's background in proteomics and genomics will help cement Metabolon's position as a leader in the emerging multiomics marketplace," said Rohan Hastie, Ph.D., President and CEO of Metabolon.

Michael is a seasoned sales leader with over 30 years in commercial roles, achieving high revenue growth in competitive and complex markets. Michael's extensive corporate experience in sales strategy and business development will be invaluable as Metabolon expands into new markets.

"Metabolon's industry-leading Global Discovery Panel offers rigorous analysis of biological systems to identify biomarkers, assess drug effects, and track changes in key biological pathways," said Michael Irwin, Vice President, Global Head of Sales. "Combined with Metabolon's Integrated Bioinformatics Platform and soon-to-be-launched multiomic data analysis tools, Metabolon's services can't be matched. I'm excited for the opportunity to drive the next phase of Metabolon's growth!"

For more information about Metabolon's services, please visit:

  • Global Discovery Panel: https://www.metabolon.com/resources/ebooks/global-panel/
  • Integrated Bioinformatics Platform:https://www.metabolon.com/bioinformatics/

About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

Logo - https://mma.prnewswire.com/media/1671125/Metabolon_Inc_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/metabolon-appoints-michael-irwin-as-vice-president-global-head-of-sales-302350015.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.